Indietro

Poster

Antiretroviral therapy

P 1
Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in people living with HIV-1 aged over 60 years
Abstract
Poster
Commento
P 2
Description of a cohort of people with HIV infection on long-acting antiretroviral therapy
Abstract
P 3
Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study
Abstract
Poster
Commento
P 4
Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine
Abstract
Poster
P 5
Improved lipid profiles in adults living with HIV receiving doravirine-based regimens: week 52 analysis
Abstract
Poster
P 6
Feasibility of cabotegravir and rilpivirine long-acting injection specific program in a large center in Northern Italy: adherence, tolerability and costs
Abstract
Poster
Commento
P 7
Outdated Antiretroviral Regimens (OLD-ART): A Cross-Sectional Study on the Achilles' Heel of Outpatient Care
Abstract
Poster
P 8
Experience with the use of prolonged-release injectable CAB/RPV in outpatients
Abstract
Poster
P 9
Cost/effectiveness analysis and assessment of adverse events associated with the administration of the long-acting cabotegravir - rilpivirine association
Abstract
Poster
Commento
P 10
Unconventional use of Long-Acting CAB+RPV against HIV in PWH in need: real-world data at 48 weeks from an Italian bicentric cohort
Abstract
Poster
P 11
Central Nervous System and Neuropsychiatric adverse events in Women Living with HIV treated with INSTI-based regimens
Abstract
Poster
P 12
Switching from 3TC/DTG and RPV/DTG to Triple Drug and Dual PI-Based therapies for toxicity/intolerance: data from the ICONA cohort
Abstract
Poster
P 13
Efficacy and safety of B/F/TAF in naïve people with HIV: real life data from the SHiNE and SHiC cohorts
Abstract
Poster
P 14
Antiretroviral therapy: consumption, costs and demographic profile of patients treated at a University Hospital in Italy in 2023
Abstract
Poster
Commento
P 15
Real-life use of doravirine in ART-Experienced PLWH bearing drug resistance mutations: findings from a monocentric cohort study
Abstract
Poster
P 16
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study)
Abstract
Poster
Commento
P 17
Insights into patients perspectives: identifying barriers in the transition from oral to injectable antiretroviral treatment
Abstract
Poster
P 18
Therapeutic switch to long acting cabotegravir/rilpivirine to overcome malabsorption due to ulcerative colitis in a person living with HIV, a case report
Abstract
Poster
P 19
High lipid levels in patients living with HIV undergoing triple antiretroviral therapy
Abstract
Poster
P 20
A real-life study in HIV-infected patients on NNRTI-regimen undergoing therapeutic optimization
Abstract
Poster
Commento
P 21
Efficacy and safety of switching to co-formulated DOR/TDF/3TC in HIV-1-infected, ART experienced adults: data from a single Italian Center in Florence, Italy
Abstract
Poster
P 22
Durability of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of treatment-experienced people with HIV: a retrospective observational study
Abstract
Poster
P 23
Durability and effectiveness of dual versus triple INSTI-based antiretroviral therapy in a real-world cohort in Palermo
Abstract
Poster
Commento
P 24
Experienced PWH switching to 3TC/TDF/DOR in outpatient setting: real-life data on Lipid changes and ASCVD risk from an Italian multicenter cohort
Abstract
Poster
P 25
Switching to long-acting cabotegravir/rilpivirine: data from an Italian monocentric cohort
Abstract
Poster
P 26
Changing life perception in a heavy treated population living with HIV after long-acting regimen introduction
Abstract
Poster
Commento
P 27
Virological failures in newly discovered people living with HIV treated with TAF/FTC/BIC as first line regimen
Abstract
Poster
P 28
Treatment experienced PWH switching to 3TC/TDF/DOR: lipid profile changes over 144 Weeks of follow up in a single-center Italian cohort
Abstract
Poster
P 29
Efficacy and tollerability of INI-based 2-drug regime in viro-suppressed patients: a sistematic review and a meta-analysis
Abstract
Poster
P 30
Switch from Ibalizumab to Lenacapavir in a salvage therapy for a patient with multidrug-resistant HIV infection
Abstract
Poster
Commento
P 31
Optimisation of antiretroviral therapy through a spending review: a population-based approach
Abstract
Poster
Commento
P 32
Efficacy and tolerability of long-acting Cabotegravir/Rilpivirine in real-world setting, 52 weeks results
Abstract
Poster
P 33
Long-Acting injectable regimen with Cabotegravir + Rilpivirine in people living with HIV: real-life experience from Modena HIV Clinic
Abstract
Poster
Commento
P 34
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability
Abstract
Poster
Commento
P 35
Preliminary real world experience in a cohort of PLWH undergoing LA CAB/RPV in Latina: a heterogeneous population with homogeneous efficacy and satisfaction
Abstract
Poster
P 36
Long-acting injectable antiretroviral therapy: pursuing equity of access through shared decision-making
Abstract
Poster
P 37
Feasibility of 3TC/DTG as a first-line strategy in the setting of rapid ART initiation: a retrospective study from the Pisan Cohort
Abstract
Poster
P 38
Evaluation of resistance-associated mutations to nucleotide reverse transcriptase inhibitors in patients treated with tenofovir disoproxil/lamivudine/doravirine
Abstract
Poster
P 39
Two is a company: results from a multicenter cohort of PLWHIV starting dolutegravir plus lamivudine as first-line regimen
Abstract
Poster
P 40
The Long Acting Therapy with CAB/RPV: experience at the Infectious Diseases Clinic of Perugia
Abstract
Poster
Commento
P 41
Sexual quality of life and genital compartment inflammation in a cohort of patients undergoing long-acting cabotegravir/rilpivirine therapy
Abstract
Poster
P 42
Fostemsavir plus doravirine for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multi-drug resistant (MDR) HIV-1 infection: 48 weeks results in a real-life setting
Abstract
Poster
P 43
Incidence of transmitted drug resistance mutations among newly diagnosed HIV‐1 patients: a 6-month retrospective analysis
Abstract
Poster
Commento
P 44
Cost-effectiveness of cabotegravir-rilpivirine LA vs. lamivudine/abacavir/dolutegravir and vs. bictegravir/emtricitabine/tenofovir in the treatment of HIV+ patients in Italy, a short-term analysis
Abstract
Poster
Commento
P 45
Carotid Intima Media Thickness is increased in adolescent and young adults living with HIV
Abstract
Poster
P 46
20-year review of neurological outcomes in HIV-exposed uninfected children in a pediatric HIV referral center
Abstract
Poster
| Privacy policy | Cookies policy | Termini e condizioni di utilizzo |
© Effetti srl
P. IVA 10756900154
×

Commento audio

Chiudi